Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

The study also found that patients with a later best confirmed response to therapy demonstrated improved outcomes compared with patients who experienced an early best confirmed response. A secondary ...

In this interview, Cerba Research explains how its teams were able to assess clinical response in multiple myeloma (MM) patients that were receiving monoclonal antibodies treatment. In multiple ...

Iberdomide combined with Darzalex and dexamethasone significantly improved MRD negativity rates in relapsed or refractory multiple myeloma patients. The EXCALIBER-RRMM trial continues to evaluate ...

Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses. More than 70% of ...